Blueprint medicines corporation (BPMC)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Cash flows from operating activities
Net loss

-347,694

-236,642

-148,119

-72,495

-52,769

-40,285

-20,912

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

5,259

4,246

1,578

1,582

948

622

501

Noncash lease expense

4,991

-

-

-

-

-

-

Noncash interest expense

-

-

-

-

109

85

26

Change in fair value of warrant liability

-

-

-

-

445

100

-4

Stock-based compensation

54,653

30,534

12,523

6,140

5,180

2,326

351

Accretion of premiums and discounts on investments

-4,949

-4,381

-320

301

-

-

-

Other

-

-6

32

73

-

-

-

Changes in assets and liabilities:
Accounts receivable

599

-349

413

-

-

-

-

Unbilled accounts receivable

22,597

151

-3,577

-

3,414

-

-

Prepaid expenses and other current assets

3,338

-6,086

6,853

-1,307

1,482

469

-16

Other assets

-20

4,242

458

304

552

-

-20

Accounts payable

1,448

-445

1,532

4

1,391

-512

541

Accrued expenses

36,980

24,804

14,597

5,773

1,956

2,873

550

Deferred revenue

-94

5,479

-11,861

33,594

13,641

-

-

Deferred rent

-

-640

14,320

-488

2,871

-140

-114

Operating lease liabilities

-2,095

-

-

-

-

-

-

Net cash used in operating activities

-278,015

-175,009

-119,865

-24,513

-31,676

-35,400

-19,025

Purchases of property and equipment

14,013

12,677

15,512

2,354

4,883

700

257

Restricted cash

-

-

-

-

1,196

-

-

Purchases of investments

738,387

801,236

360,835

264,467

-

-

-

Maturities of investments

735,934

652,825

304,000

48,000

-

-

-

Net cash provided by investing activities

-16,466

-161,088

-72,347

-218,821

-6,079

-700

-257

Proceeds from term loan

-

-

-

-

-

7,000

3,000

Principal payments on loan payable

-

1,528

2,583

3,333

1,806

750

-

Payment of offering costs

284

281

965

143

2,046

-

-

Proceeds from public offerings of common stock, net of commissions, underwriting discounts and offering costs

327,750

-

542,225

135,125

156,815

-

-

Debt issuance costs

-

-

-

-

-

18

48

Proceeds from issuance of common stock

13,288

6,425

5,271

928

259

268

53

Other financing activities

-116

-162

-

-

-

-

-

Net cash provided by financing activities

340,638

4,454

543,948

132,577

153,222

81,353

17,992

Net increase in cash, cash equivalents, and restricted cash

46,157

-331,643

351,736

-110,757

115,467

45,253

-1,290

Effect of exchange rate changes on cash, cash equivalents and restricted cash

18

-

-

-

-

-

-

Supplemental cash flow information
Public offering costs incurred but unpaid at period end

-

-

317

433

-

-

-

Property and equipment purchases unpaid at period end

958

912

3,947

-

1,244

-

-

Conversion of convertible preferred stock into common stock

-

-

-

-

114,808

-

-

Reclassification of warrant liability to additional paid-in-capital

-

-

-

-

810

-

-

Cash paid for interest

5

267

151

316

452

215

53

Cash paid for taxes, net

185

123

37

-

-

-

-

Issuance of warrants in connection with term loan

-

-

-

-

-

145

119